Vivo Capital, LLC Q1 2017 Filing
Filed May 15, 2017
Portfolio Value
$339.9B
Holdings
23
Report Date
Q1 2017
Filing Type
13F-HR
All Holdings (23 positions)
| # | Stock | Shares | Value | % Portfolio | Type |
|---|---|---|---|---|---|
| 1 | ACRSAclaris therapeutics | 2,858,569 | $85.2B | 25.08% | |
| 2 | ASNDAscendis Pharma | 1,766,832 | $49.5B | 14.55% | |
| 3 | —Nabriva Therapeutics AG | 4,021,559 | $48.3B | 14.20% | |
| 4 | CDXSCodexis, Inc. | 5,294,825 | $25.4B | 7.48% | |
| 5 | CLDNEUREiger BioPharmaceuticals | 1,787,091 | $20.5B | 6.02% | |
| 6 | —Advanced Accelerator Applications S.A. | 483,786 | $19.3B | 5.67% | |
| 7 | —Aimmune Therapeutics, Inc. | 763,009 | $16.6B | 4.88% | |
| 8 | —Strongbridge Biopharma plc | 3,000,000 | $14.3B | 4.19% | |
| 9 | —Capnia, Inc. | 14,695,264 | $10.4B | 3.07% | |
| 10 | —BioPharmX Corporation | 12,814,286 | $6.5B | 1.90% | |
| 11 | —Trevena, Inc. | 1,728,000 | $6.3B | 1.87% | |
| 12 | —Akari Therapeutics Plc | 527,842 | $5.8B | 1.72% | |
| 13 | —Agile Therapeutics, Inc. | 1,513,975 | $4.9B | 1.43% | |
| 14 | AUPHAurinia Pharmaceuticals Inc. | 600,000 | $4.4B | 1.30% | |
| 15 | —Foamix Pharmaceuticals Ltd. | 855,000 | $4.2B | 1.24% | |
| 16 | —Sierra Oncology Inc. | 2,438,270 | $3.7B | 1.10% | |
| 17 | CRSPCRISPR Therapeutics AG | 148,878 | $3.2B | 0.95% | |
| 18 | RGNXRegenxbio Inc. | 164,403 | $3.2B | 0.93% | |
| 19 | KALVKalVista Pharmaceuticals, Inc. | 300,325 | $2.3B | 0.69% | |
| 20 | DVAXDynavax Technologies Corporation | 359,828 | $2.1B | 0.63% | |
| 21 | —Sunesis Pharmaceuticals, Inc. | 500,000 | $2.0B | 0.60% | |
| 22 | RVNCEURReVance Therapeutics, Inc. | 77,373 | $1.6B | 0.47% | |
| 23 | —Capnia, Inc. | 943,858 | $113.0M | 0.03% |